These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

288 related items for PubMed ID: 6850619

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors.
    Hengst JC, Mokyr MB, Dray S.
    Cancer Res; 1981 Jun; 41(6):2163-7. PubMed ID: 7016310
    [Abstract] [Full Text] [Related]

  • 4. Cyclophosphamide-induced appearance of immunopotentiating T-cells in the spleens of mice bearing a large MOPC-315 tumor.
    Ye QW, Mokyr MB.
    Cancer Res; 1984 Sep; 44(9):3873-9. PubMed ID: 6611201
    [Abstract] [Full Text] [Related]

  • 5. Importance of Lyt 2+ T-cells in the curative effectiveness of a low dose of melphalan for mice bearing a large MOPC-315 tumor.
    Mokyr MB, Barker E, Weiskirch LM, Takesue BY, Pyle JM.
    Cancer Res; 1989 Aug 15; 49(16):4597-606. PubMed ID: 2568174
    [Abstract] [Full Text] [Related]

  • 6. Some characteristics of the cyclophosphamide-induced immunopotentiating cells in the spleen of mice bearing a large MOPC-315 tumor.
    Mokyr MB, Ye QW.
    Cancer Res; 1985 Oct 15; 45(10):4932-9. PubMed ID: 4027979
    [Abstract] [Full Text] [Related]

  • 7. Ability of cyclophosphamide in the absence of cross-linking activity to exert the immunomodulatory effect required for the cure of mice bearing a large MOPC-315 tumor.
    Mokyr MB, Brundrett RB, Colvin M, Dray S.
    Cancer Res; 1986 Jul 15; 46(7):3313-20. PubMed ID: 3486709
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Melphalan-induced enhancement of antitumor immune reactivity in thymocytes of adult BALB/c mice bearing a large MOPC-315 tumor.
    Bartik MM, Takesue BY, Mokyr MB.
    Cancer Res; 1987 Sep 15; 47(18):4848-55. PubMed ID: 3497711
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Importance of the B7-2 molecule for low dose melphalan-induced acquisition of tumor-eradicating immunity by mice bearing a large MOPC-315 tumor.
    Mokyr MB, Kalinichenko TV, Gorelik L, Bluestone JA.
    J Immunol; 1998 Feb 15; 160(4):1866-74. PubMed ID: 9469448
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Induction by cyclophosphamide administration of two distinct anti-tumor effector cells at tumor site and spleen of mice transplanted with MOPC-104E plasmacytoma.
    Nio Y, Ohgaki K, Tobe T.
    J Clin Lab Immunol; 1989 May 15; 29(1):37-43. PubMed ID: 2534133
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Immunity against MOPC 104E plasmacytoma: effects of tumor size and time post therapy on in vivo tumor immunity.
    Lubet RA, Carlson DE.
    J Natl Cancer Inst; 1978 May 15; 60(5):1107-11. PubMed ID: 642029
    [Abstract] [Full Text] [Related]

  • 19. Lysis of antigenically unrelated tumor cells mediated by Lyt 2+ splenic T-cells from melphalan-cured MOPC-315 tumor bearers.
    Barker E, Wise JA, Dray S, Mokyr MB.
    Cancer Res; 1989 Sep 15; 49(18):5007-15. PubMed ID: 2788494
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.